Updates About the Expanded Access Program for MN-166 in ALS
Program to provide investigational drug to ALS patients who would otherwise be ineligible for clinical trialsSAN JOSE, Calif., June 29,...
Program to provide investigational drug to ALS patients who would otherwise be ineligible for clinical trialsSAN JOSE, Calif., June 29,...
Dario's best-in-class, consumer-centric chronic care platform, combined now with Beluga's embedded clinical delivery, extends member engagement to include provider-delivered treatment,...
Torino, Italy, June 29, 2026 – Resalis Therapeutics today announced the dosing of the first participant in a Phase 1b...
Patient enrollment has been completed; all enrolled patients remain aliveData presented at the Nuclear Medicine and Neuro-Oncology (NMN) Society Annual...
Oslo, Norway, 29 June 2026: Reference is made to the stock exchange announcement published by Zelluna ASA (the “Company”) on...
Veteran life sciences executive brings over 30 years of strategic and commercial leadership as Aplagon advances through Phase 2 development...
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time...
Non-contrast, ventilation-perfusion imaging—from routine chest CT scansMELBOURNE, Australia, June 28, 2026 /PRNewswire/ -- 4DMedical Limited (ASX: 4DX), the global leader...